WuXi AppTec’s orders and margins rise, while overseas expansion costs and US policy still shape the outlook
Third-quarter profit grew faster than revenue, and the company raised its full-year guidance again. JPMorgan sees growth from late-stage projects and commercial manufacturing, but the timing of large-order deliveries and the ramp-up of overseas capacity will affect when results materialize.
Original source：J.P. MorganFirst published on Unhidea：Original source date：
Key takeaway
WuXi AppTec’s growth is being driven by late-stage and commercial projects. Improving orders and margins have prompted JPMorgan to raise its earnings forecasts, but delivery timing, overseas expansion costs and US policy still affect the realization of growth.
What changes in the third quarter drove the increase in full-year guidance?
WuXi AppTec’s revenue in the third quarter of 2026 was 16.64 billion yuan, up 38% year on year; adjusted net profit was 6.81 billion yuan, up 61% year on year. Revenue from continuing operations grew 43.5% year on year.
Management raised its 2026 revenue guidance from 58.5 billion–60.5 billion yuan to 61 billion–61.9 billion yuan, and lifted its revenue growth guidance for continuing operations from 35%–39% to 40%–42%.
JPMorgan raised its revenue forecasts for 2026–2028 by approximately 2% and increased its gross margin and adjusted net margin assumptions by approximately 3 percentage points each, raising its earnings forecasts by 10%–12%. The bank raised its A-share and H-share price targets from 200 yuan and 222 Hong Kong dollars to 210 yuan and 233 Hong Kong dollars, respectively, and maintained its overweight rating.
Why is profit growing faster than revenue?
In the first three quarters of 2026, revenue from small-molecule research, development and manufacturing grew 66% year on year to 23.58 billion yuan, driving 51.5% growth in chemistry business revenue. Management expects full-year revenue from small-molecule research, development and manufacturing to grow by more than 50%.
JPMorgan believes that faster growth in higher-value late-stage and commercial small-molecule projects, together with improved production efficiency, drove the chemistry business’s adjusted gross margin up 5.9 percentage points year on year to 57.1%.
AI drug discovery clients are also generating demand for high-throughput experiments and model-training data generation. The company has not quantified related revenue or orders; JPMorgan expects related sales to grow from a low base.
How can new orders support future revenue?
At the end of September 2026, the backlog for continuing operations was 76.74 billion yuan, up 36.4% year on year. Management said new orders in the first three quarters grew by more than 60%, and new orders in the third quarter exceeded 27 billion yuan, mainly from late-stage and commercial chemistry projects.
Management expects the vast majority of the backlog to be delivered within 18 months, but larger orders have longer delivery cycles and uneven schedules. JPMorgan therefore believes order growth supports sustained revenue growth but cannot be directly equated with the revenue growth rate in 2027.
How does capacity expansion affect cash flow and margins?
The company raised its 2026 adjusted free cash flow guidance from 13.5 billion–14.5 billion yuan to 14.5 billion–15.5 billion yuan, while raising the lower end of its capital expenditure range to 8 billion yuan, making the new range 8 billion–8.5 billion yuan.
Management preliminarily expects capital expenditure to increase further in 2027; the ramp-up of overseas capacity and depreciation may cause short-term margin fluctuations. The company is confident that its adjusted net margin will remain stable in 2026, but did not provide a specific target.
Why is US policy risk considered to have declined?
Management said that, as of the conference call, the company had not received notice that the US Office of Management and Budget intended to designate it a “biotechnology company of concern.” Under management’s legal interpretation, another designation pathway requires advance notice and a 90-day period to respond; JPMorgan consequently judged that the related risk had declined.
Management believes the preliminary injunction in the 1260H litigation prevents the company from being automatically designated through that pathway, but does not rule out a separate interagency review led by the US Office of Management and Budget.
